Recursion Pharmaceuticals Ownership | Who Owns Recursion Pharmaceuticals?
Recursion Pharmaceuticals Ownership Summary
Recursion Pharmaceuticals is owned by 53.05% institutional investors, 2.30% insiders, and 44.65% retail investors. Vanguard group is the largest institutional shareholder, holding 10.56% of RXRX shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 4.25% of its assets in Recursion Pharmaceuticals shares.
RXRX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Recursion Pharmaceuticals | 53.05% | 2.30% | 44.65% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vanguard group | 47.19M | 10.56% | $193.00M |
| Blackrock funding, inc. /de | 43.19M | 9.65% | $132.60M |
| Ark investment management | 40.21M | 8.99% | $123.45M |
| Blackrock | 17.31M | 7.33% | $129.83M |
| State street | 28.49M | 6.37% | $87.47M |
| Baillie gifford | 23.68M | 5.29% | $72.68M |
| Kinnevik ab (publ) | 13.43M | 3.22% | $65.56M |
| Mubadala investment co pjsc | 12.99M | 3.11% | $63.37M |
| Softbank group | 13.64M | 3.05% | $41.86M |
| Geode capital management | 12.28M | 2.74% | $37.69M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Kinnevik ab (publ) | 13.43M | 100.00% | $65.56M |
| Dcvc opportunity fund ii gp | 3.95M | 87.48% | $12.13M |
| Data collective iv gp | 5.94M | 32.60% | $18.24M |
| Mic capital management uk llp | 9.64M | 8.40% | $29.61M |
| Novo | 7.93M | 2.49% | $38.70M |
| Nan fung group | 595.29K | 1.51% | $1.83M |
| Nvidia | 7.71M | 0.98% | $37.61M |
| Ark investment management | 40.21M | 0.96% | $123.45M |
| Carroll investors | 509.43K | 0.84% | $1.56M |
| Pivotal bioventure partners investment advisor | 595.52K | 0.65% | $1.83M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vanguard group | 47.19M | 0.00% | 7.41M |
| Norges bank | 5.74M | 0.00% | 5.74M |
| Blackrock | 17.31M | 0.00% | 4.99M |
| Blackrock funding, inc. /de | 43.19M | 0.00% | 4.33M |
| Goldman sachs group | 6.07M | 0.00% | 3.86M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ra capital management | - | - | -7.73M |
| Citadel advisors | 624.66K | 0.00% | -3.61M |
| Morgan stanley | 2.19M | 0.00% | -3.47M |
| Fmr | 736.65K | 0.00% | -2.51M |
| Deerfield management company, l.p. (series c) | - | - | -2.31M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Norges bank | 5.74M | 0.00% | 5.74M | $23.47M |
| Vanguard fiduciary trust | 3.51M | 0.00% | 3.51M | $10.79M |
| Renaissance | 2.40M | 0.01% | 2.40M | $7.37M |
| Mitsubishi ufj trust & banking | 908.46K | 0.01% | 908.46K | $2.79M |
| Vanguard asset management | 421.37K | 0.00% | 421.37K | $1.29M |
Sold Out
| Holder | Change |
|---|---|
| Nbc securities | -1.00 |
| Tfc financial management | -1.00 |
| Financial gravity asset management | -4.00 |
| Parallel advisors | -7.00 |
| Bayforest capital | -7.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 261 | -24.57% | 237,387,622 | -26.79% | 53 | 1.01% | 147 | -23.04% | 60 | -30.23% |
| Dec 31, 2025 | 281 | -19.25% | 291,943,780 | -10.14% | 65 | 1.08% | 149 | -16.29% | 69 | -14.81% |
| Sep 30, 2025 | 331 | -6.76% | 323,965,396 | 4.44% | 77 | 1.41% | 170 | -3.41% | 78 | -8.24% |
| Jun 30, 2025 | 341 | -2.01% | 308,955,617 | 7.04% | 74 | 1.44% | 170 | -16.67% | 85 | 21.43% |
| Mar 31, 2025 | 350 | 4.79% | 304,203,724 | -0.17% | 75 | 0.65% | 204 | 2.51% | 72 | 14.29% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ARK Disruptive Innovation Full Composite | 22.43M | 4.25% | 1.91M |
| ARK Innovation ETF | 21.73M | 4.11% | -1.59M |
| State Street® SPDR® S&P® Biotech ETF | 18.65M | 3.53% | -184.50K |
| Scottish Mortgage Ord | 18.17M | 3.42% | - |
| Vanguard Total Stock Mkt Idx Inv | 15.68M | 2.95% | 78.13K |
| ARK Genomic Revolution ETF | 12.55M | 2.38% | 531.09K |
| ARK Genomic Revolution | 11.84M | 2.24% | 162.06K |
| Vanguard Small Cap Index | 11.41M | 2.15% | -22.38K |
| iShares Russell 2000 ETF | 10.73M | 2.02% | 90.43K |
| Vanguard US Total Market Shares ETF | 8.01M | 1.99% | 1.01M |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 05, 2026 | Gibson Christopher | - | Sell | $144.80K |
| Jun 05, 2026 | Khan Najat | CEO and President | Sell | $84.46K |
| Jun 03, 2026 | Bumpus Namandje | - | Sell | $15.53K |
| Jun 02, 2026 | Borgeson Blake | - | Sell | $110.40K |
| May 22, 2026 | Gibson Christopher | - | Sell | $123.20K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 10 |
| 2026 Q1 | - | 11 |
| 2025 Q4 | - | 9 |
| 2025 Q3 | - | 6 |
| 2025 Q2 | - | - |
RXRX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools